Deutsche Bank
VIGL

Deutsche Bank’s Vigil Neuroscience VIGL Stock Holding History

Deutsche Bank’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,747
Closed -$26K – 4336
2022
Q1 		$26K Buy
+3,747
New +$49.4K ﹤0.01% 4009

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Deutsche Bank's VIGL Position: Q2 2022 in Review

Deutsche Bank sold out of Vigil Neuroscience (VIGL) in Q2 2022, closing a stake of 3,747 shares — an estimated $26K sold.

Deutsche Bank first reported a position in VIGL in Q1 2022 and held it in 1 quarter. The position peaked at $26K in Q1 2022. 35 funds tracked by Wall St. Rank hold VIGL as of Q2 2022.

  • Deutsche Bank reported no remaining Vigil Neuroscience position as of Q2 2022 after selling out during the quarter.
  • Deutsche Bank sold 3,747 Vigil Neuroscience shares in Q2 2022, an estimated $26K.
  • Deutsche Bank first reported a position in Vigil Neuroscience in Q1 2022 and held it in 1 quarter.
  • Deutsche Bank's Vigil Neuroscience position peaked at $26K in Q1 2022.
  • 35 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2022.

Based on Deutsche Bank's 13F filing for Q2 2022, filed 11 Aug 2022.